[{"id":"4b0f1350-ce19-4057-8fd9-f2b662d41e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06025747","created_at":"2023-09-06T14:09:40.441Z","updated_at":"2025-02-25T16:55:17.296Z","phase":"Phase 1","brief_title":"Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma","source_id_and_acronym":"NCT06025747","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/09/2025","start_date":" 02/09/2025","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2026","study_completion_date":" 03/03/2026","last_update_posted":"2025-02-04"},{"id":"676dfb5a-6692-4639-bd2b-6232077e3caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896335","created_at":"2021-01-18T14:12:49.075Z","updated_at":"2025-02-25T16:05:12.381Z","phase":"Phase 2","brief_title":"Palbociclib and Pembrolizumab in Central Nervous System Metastases","source_id_and_acronym":"NCT02896335","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" CCNE1 amplification • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-11-21"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"fbf4520a-0024-4ad4-aacb-7c70b6344b99","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074785","created_at":"2021-01-18T19:57:29.190Z","updated_at":"2024-07-02T16:35:08.254Z","phase":"Phase 1","brief_title":"Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6","source_id_and_acronym":"NCT04074785","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • RB1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 10/24/2025","study_completion_date":" 10/24/2025","last_update_posted":"2024-04-22"},{"id":"cb3171df-fc1d-4edc-a68b-8e666a6750ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04391595","created_at":"2021-01-18T21:11:39.818Z","updated_at":"2024-07-02T16:35:12.669Z","phase":"Phase 1","brief_title":"LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients","source_id_and_acronym":"NCT04391595","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-27"},{"id":"3fe15ba6-c8bd-43a0-9070-1c6451e7aaf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310879","created_at":"2021-01-18T16:21:04.198Z","updated_at":"2024-07-02T16:35:20.810Z","phase":"Phase 2","brief_title":"Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6","source_id_and_acronym":"NCT03310879","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/21/2017","start_date":" 11/21/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-02-06"},{"id":"b39d6f05-f231-4745-aadd-73899fae2d7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594005","created_at":"2021-01-19T20:29:03.455Z","updated_at":"2024-07-02T16:35:34.460Z","phase":"Phase 1/2","brief_title":"CDK4/6 Tumor, Abemaciclib, Paclitaxel","source_id_and_acronym":"NCT04594005","lead_sponsor":"Yonsei University","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/25/2021","start_date":" 02/25/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2023-10-06"},{"id":"43035839-3bf9-43e5-bbd5-afd4d6d1337c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02981940","created_at":"2021-01-18T14:40:08.944Z","updated_at":"2024-07-02T16:35:41.812Z","phase":"Phase 2","brief_title":"A Study of Abemaciclib in Recurrent Glioblastoma","source_id_and_acronym":"NCT02981940","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B • CDK6","pipe":" | ","alterations":" CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type","tags":["CDKN2A • RB1 • CDK4 • CDKN2B • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-27"},{"id":"4d8abee9-1474-4364-a705-95320d1ba771","acronym":"ABORL","url":"https://clinicaltrials.gov/study/NCT03356223","created_at":"2021-01-18T16:34:03.658Z","updated_at":"2024-07-02T16:35:54.832Z","phase":"Phase 2","brief_title":"Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6","source_id_and_acronym":"NCT03356223 - ABORL","lead_sponsor":"Centre Leon Berard","biomarkers":" CDKN2A • CCND1","pipe":" | ","alterations":" CDKN2A deletion • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 11/05/2022","primary_completion_date":" 11/05/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-02-23"},{"id":"4ccc2c43-cf80-4471-8f20-ea4d38f5f9ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01037790","created_at":"2021-01-18T04:04:21.968Z","updated_at":"2024-07-02T16:36:33.413Z","phase":"Phase 2","brief_title":"Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer","source_id_and_acronym":"NCT01037790","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2","pipe":" | ","alterations":" KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation","tags":["HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2021-03-11"},{"id":"592b7eaa-b0b9-44ec-a9e0-7a40a914198a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02264613","created_at":"2021-01-18T10:39:31.889Z","updated_at":"2024-07-02T16:36:43.300Z","phase":"Phase 1/2","brief_title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02264613","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53 • MDM2 • CDK4","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification • CDK4 amplification","tags":["TP53 • MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2020-07-14"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"},{"id":"c1c59569-4d0e-46ee-bb17-66b111568989","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454919","created_at":"2021-01-18T17:02:06.573Z","updated_at":"2024-07-02T16:37:13.272Z","phase":"Phase 2","brief_title":"Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations","source_id_and_acronym":"NCT03454919","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" CDKN2A • CCND1 • CDK4","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2018-03-06"},{"id":"019190f6-b3b4-4137-a38e-909fc259d271","acronym":"","url":"https://clinicaltrials.gov/study/NCT01209598","created_at":"2021-01-17T17:45:39.803Z","updated_at":"2024-07-02T16:37:16.651Z","phase":"Phase 2","brief_title":"PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma","source_id_and_acronym":"NCT01209598","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 09/23/2010","start_date":" 09/23/2010","primary_txt":" Primary completion: 10/25/2016","primary_completion_date":" 10/25/2016","study_txt":" Completion: 10/25/2016","study_completion_date":" 10/25/2016","last_update_posted":"2017-11-06"},{"id":"e7a44796-80e3-42de-b687-90778b859f58","acronym":"","url":"https://clinicaltrials.gov/study/NCT02671513","created_at":"2021-01-18T13:01:26.288Z","updated_at":"2024-07-02T16:37:32.830Z","phase":"Phase 1","brief_title":"A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients","source_id_and_acronym":"NCT02671513","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CDKN2A • CCND1 • CDK4","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • CCND1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2016-04-12"}]